Recruiting

Observational Study

Sponsor:

University of British Columbia

Code:

NCT02006134

Conditions

Wegeners Granulomatosis (Granulomatosis With Polyangiitis)

Microscopic Polyangiitis

Eosinophilic Granulomatosis With Polyangiitis

Polyarteritis Nodosa

Takayasu Arteritis

Eligibility Criteria

Sex: All

Age: 0 - 20

Healthy Volunteers: Accepted

Study Details

Brief summary:

Childhood chronic vasculitis describes a group of rare life-threatening diseases that have in common inflammation of blood vessels in vital organs such as kidneys, lungs and brain. Most knowledge about them comes from adult patients. Severe disease requires aggressive life-saving treatments with steroids and some cancer drugs which can themselves cause damage, and increase risks of cancer and severe infections. Conversely, milder disease can be treated with less toxic drugs. Different classification and "scoring tools" are used to define the types and severity of vasculitis and to measure damage caused by disease or drugs. These in turn help direct how aggressively to treat a patient and to measure outcome. None of these tools however have been assessed in children and the best balance of disease and treatment risks against outcome for children is not known. Although causes of these diseases in children and adults are probably the same, the effects of the disease and the response (good and bad) to drugs will differ in growing children. Because specialists may see only one new child with vasculitis each year, obtaining enough information to learn about childhood vasculitis requires cooperation. We will use an international web-based registry to which doctors from 50 or more centers can contribute patient data. We will determine the features which help better classify and diagnose children compared to adults. Through the web we will collect and analyze information on patients similarly classified and "scored" so that most successful treatments can be identified. Children with vasculitis are less likely to have diseases associated with aging, alcohol and smoking etc., and therefore may be a better group in whom to study the underlying biology of vasculitis. We will use this opportunity and collect spit, blood and tissue from registry patients for laboratory study with an aim to find biomarkers to better classify, define and direct optimal treatment and outcomes.

Conditions

Wegeners Granulomatosis (Granulomatosis With Polyangiitis)

Microscopic Polyangiitis

Eosinophilic Granulomatosis With Polyangiitis

Polyarteritis Nodosa

Takayasu Arteritis

Study ID

NCT02006134

Start date

Jan, 2013

Status verified date

Nov, 2023

Completion date

Mar, 2025

Anticipated

Primary completion date

Mar, 2025

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0 - 20

Healthy Volunteers: Accepted

Inclusion criteria for vasculitis subjects:

  • Diagnosed with ANCA-associated vasculitis (AAV: such as Granulomatosis with Polyangiitis (GPA), Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Microscopic Polyangiitis (MPA)), Primary Angiitis of the Central Nervous System (PACNS), Unclassified vasculitis, Takayasu's Arteritis (TA) or Polyarteritis Nodosa (PAN) before age 18

Inclusion criteria for healthy controls:

  • Healthy adult or child

Exclusion Criteria for vasculitis subjects:

  • Diagnosed with other vasculitis subtypes not listed above
  • More than 20 years of age

Exclusion criteria for healthy controls:

  • Donated greater than 20 ml of blood in the previous three weeks
  • Has an immune disorder or blood borne infectious diseases (such as HIV or Hepatitis)
  • Has vasculitis, multiple sclerosis, diabetes, an autoimmune disease, a thyroid condition, or other chronic conditions involving the heart, lungs, gut or kidney
  • Has a previous history of anaemia or abnormal blood clotting
  • Has a current or previous drug abuse problem

Study Design

Enrollment

1600 participants

Anticipated

Interventions and Outcome Measures

Arms

PEDIATRIC VASCULITIS/PROSPECTIVE

Pediatric patients in this cohort are those diagnosed with vasculitis within 12 months from study entry. Clinical data, blood (RNA, plasma, serum), urine, and saliva (DNA) will be collected at 3 to 5 timepoints: time-of-diagnosis, post-induction, 12-month post diagnosis, disease flare, and remission/post-flare.

PEDIATRIC VASCULITIS/RETROSPECTIVE

Patients in this cohort are those diagnosed with vasculitis more than 12 months from study entry and/or were previously enrolled in the ARChiVe or Brainworks registries. Clinical outcome data will be collected retrospectively. Blood (RNA \& serum), urine, and saliva (DNA) will be collected at 2 timepoints: disease flare, and remission/post-flare.

Primary outcome measure

  • Develop new benchmarks for outcome in pediatric patients with systemic vasculitis [ Time Frame: within 3 yrs ]

Central Contacts and Locations

Central contacts

Else S. Bosman, PhD

pedvas@cw.bc.ca

Locations

University of San Francisco

Recruiting

San Francisco, California, United States

Principal Investigator:

Susan Kim, MD

University of Florida

Recruiting

Gainesville, Florida, United States

Principal Investigator:

Melissa Elder, MD, PhD

Comer Children's Hospital

Recruiting

Chicago, Illinois, United States

Principal Investigator:

Linda Wagner-Weiner

Riley Hospital for Children

Recruiting

Indianapolis, Indiana, United States

Principal Investigator:

Stacey Tarvin

The Joseph M. Sanzari Children's Hospital

Recruiting

Hackensack, New Jersey, United States

Principal Investigator:

Suzanne Li, MD

Children's Hospital at Montefiore

Recruiting

Bronx, New York, United States

Principal Investigator:

Dawn Wahezi, MD

Akron Children's Hospital

Recruiting

Akron, Ohio, United States

Principal Investigator:

Mary Toth, MD

Texas Children's Hospital

Recruiting

Houston, Texas, United States

Principal Investigator:

Alvaro Orjuela, MD

University of Utah / Primary Children's Hospital

Recruiting

Salt Lake City, Utah, United States

Principal Investigator:

Aimee Hersh, MD

Seattle Children's Hospital

Recruiting

Seattle, Washington, United States

Principal Investigator:

Susan Shenoi

University of Calgary / Alberta Children's Hospital

Recruiting

Calgary, Alberta, Canada

Principal Investigator:

Susanne Benseler, MD, PhD

BC Children's Hospital

Recruiting

Vancouver, British Columbia, Canada

Principal Investigator:

David Cabral, MBBS

IIWK Health Centre

Recruiting

Halifax, Nova Scotia, Canada

Principal Investigator:

Adam Huber, MD

London Health Sciences Centre

Recruiting

London, Ontario, Canada

Principal Investigator:

Roberta Berard

Children's Hospital of Eastern Ontario

Recruiting

Ottawa, Ontario, Canada

Principal Investigator:

Ciaran Duffy, MD

More Information

Sponsor

University of British Columbia

Last update posted

Nov 30, 2023

Last verified

Nov, 2023

Keywords

  • Vasculitis
  • Primary CNS Vasculitis
  • Systemic vasculitis
  • Churg-Strauss Syndrome
  • Polyarteritis Nodosa
  • Wegener Granulomatosis
  • Pediatric vasculitis
  • Childhood vasculitis
  • Granulomatosis with polyangiitis
  • Microscopic Polyangiitis
  • Takayasu Arteritis
  • Autoimmune
  • ANCA-associated vasculitis

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by University of British Columbia on 2023-11-30.